Skip to search formSkip to main contentSkip to account menu

ersentilide

Known as: 4-HIPPM, N-(4-(2-hydroxy-3-((2-(4-(1H-imidazol-1-yl)phenoxy)ethyl)amino)propoxy)phenyl)methanesulfonamide 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (4)

CK 3579CK 4000CK 4001HE 93

Broader (2)

ImidazolesPropanolamines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
Class III drugs prolong the QT interval by blocking mainly the delayed rectifier rapid potassium outward current (IKr), with… 
Review
2003
Review
2003
IKr channel blockers: novel antiarrhythmic agents.
There have been extensive efforts to develop I(Kr) channel blockers as a new antiarrhythmic agent for atrial or ventricular… 
Review
1999
Review
1999
What Should We Expect From the Next Generation of Antiarrhythmic Drugs?
The Next Generation of Antiarrhythmic Drugs. Five drugs currently constitute approximately 70% of the world market for… 
1998
1998
Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction.
1995
1995
The electrophysiologic effects of ersentilide on canine hearts.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)